Coagulation and Haemorrhagic Disorders
Coagulation disorders present as abnormal bleeding that may be acquired or inherited. Inherited disorders include haemophilia and von Willebrand disease (VWD) that arise from deficiencies in clotting factor VIII or IX, and platelet dysfunction, respectively.
Acquired coagulation disorders can result from vitamin K deficiency, liver disease, disseminated intravascular coagulation (DIC) and high levels of circulating anticoagulants (including oral vitamin K antagonists and non-vitamin K oral anticoagulants prescribed to patients with diseases such as atrial fibrillation, heart failure, valvular heart disease and venous thromboembolism).
Featured Learning Zones
Latest Clinical Guidelines, Trials and Journals
This study attempts to observe the effectiveness and safety of aripiprazole in hospitalized patients with acute schizophrenia episode, and to compare the different drug regimens that may be involved in order to clarify the characteristics...
These updated guidelines on the management of variceal haemorrhage have been commissioned by the Clinical Services and Standards Committee (CSSC) of the British Society of Gastroenterology (BSG) under the auspices of the liver section of the BSG.
Latest news and insights
A new retrospective data analysis published in Kidney Medicine shows that a higher percentage of hemodialysis patients prescribed Velphoro (sucroferric oxyhydroxide chewable tablets), from Fresenius Medical, achieved target serum phosphorous levels of less than or equal to 5.5 mg/dL compared to those patients who
Takeda Pharmaceutical Co announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use granted a positive opinion for the extension of the marketing authorization of Adcetris (brentuximab vedotin) and recommended its approval in combination with CHP (cyclophosphamide,
Novo Nordisk announced that the New England Journal of Medicine published results of a phase III trial evaluating the investigational use of Saxenda (liraglutide) injection 3.0 mg in adolescents (aged 12– 18) with obesity.